Laboratory Corporation of America Holdings (LabCorp) has introduced a new risk stratification tool - ROMA (risk of ovarian malignancy algorithm).
The ROMA test uses the results from simple blood tests, Abbott’s Architect CA 125 II, and Fujirebio HE4, to identify patients presenting with adnexal mass.
The company said ROMA is used to assess whether a premenopausal or postmenopausal woman who presents with an ovarian adnexal mass is at high or low likelihood of finding malignancy on surgery. The test is not intended as a screening or stand-alone diagnostic assay.
LabCorp CMO Mark Brecher said ROMA when used in conjunction with clinical exam and radiological studies will assist patients in receiving the most appropriate referrals.
ROMA has received the US Food and Drug Administration approval.